IPS Examines DNDi Program To Develop Pediatric HIV Drugs
Inter Press Service profiles a program launched by the Drugs for Neglected Diseases Initiative (DNDi) to develop antiretroviral drugs (ARVs) specifically designed for children living with HIV/AIDS. “The program will focus exclusively on developing child-adapted formulations for children under three, the most neglected segment in terms of availability of ARVs. The DNDi hopes to have new pediatric-specific medicines available between 2014 and 2016,” IPS writes. The article examines pediatric HIV treatment issues in India, Kenya and Brazil (Frayssinet et al., 8/29).